首页 » BeiGene Announces the Approval in China of BLINCYTO® (Blinatumomab) for Injection for Pediatric Patients with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (ALL)
https://ir.beigene.com/news-details/?id=8be9ae63-37f7-4130-ac6d-a2316fe3c8bb